EA200401064A1 - Вирусоподобные частицы из вируса папилломы человека - Google Patents
Вирусоподобные частицы из вируса папилломы человекаInfo
- Publication number
- EA200401064A1 EA200401064A1 EA200401064A EA200401064A EA200401064A1 EA 200401064 A1 EA200401064 A1 EA 200401064A1 EA 200401064 A EA200401064 A EA 200401064A EA 200401064 A EA200401064 A EA 200401064A EA 200401064 A1 EA200401064 A1 EA 200401064A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- particles
- human papilloma
- hpv
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее изобретение относится к вакцинной композиции, которая содержит вирусоподобные частицы, содержащие белки L1 или функциональные производные белков L1 из генотипов ЧПВ 16, ЧПВ 18, ЧПВ 31 и 45.Отчет о международном поиске был опубликован 2003.12.24.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0206360.0A GB0206360D0 (en) | 2002-03-18 | 2002-03-18 | Viral antigens |
PCT/EP2003/002826 WO2003077942A2 (en) | 2002-03-18 | 2003-03-17 | Virus-like particles of human papillomavirus |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200401064A1 true EA200401064A1 (ru) | 2005-04-28 |
EA011477B1 EA011477B1 (ru) | 2009-04-28 |
Family
ID=9933201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200401064A EA011477B1 (ru) | 2002-03-18 | 2003-03-17 | Вакцинная композиция против папилломавируса человека и способы ее получения и применения |
Country Status (25)
Country | Link |
---|---|
US (3) | US7217419B2 (ru) |
EP (2) | EP1492562A2 (ru) |
JP (2) | JP2005524674A (ru) |
KR (2) | KR20050002868A (ru) |
CN (1) | CN100528226C (ru) |
AP (1) | AP1872A (ru) |
AR (1) | AR039005A1 (ru) |
AU (1) | AU2003218787B2 (ru) |
BR (1) | BR0308444A (ru) |
CA (1) | CA2479304C (ru) |
EA (1) | EA011477B1 (ru) |
EC (1) | ECSP045300A (ru) |
GB (1) | GB0206360D0 (ru) |
IL (2) | IL163814A0 (ru) |
IS (1) | IS7426A (ru) |
MX (1) | MXPA04009060A (ru) |
MY (1) | MY139031A (ru) |
NO (1) | NO20044326L (ru) |
NZ (1) | NZ535085A (ru) |
OA (1) | OA12787A (ru) |
PL (1) | PL212981B1 (ru) |
TW (1) | TW200400046A (ru) |
UA (1) | UA85536C2 (ru) |
WO (1) | WO2003077942A2 (ru) |
ZA (1) | ZA200407029B (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8956621B2 (en) * | 1994-11-08 | 2015-02-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
US8791237B2 (en) * | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
EP2266604A3 (en) * | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
ES2381964T3 (es) | 2003-03-24 | 2012-06-04 | Merck Sharp & Dohme Corp. | Expresión optimizada de L1 de VPH 31 en levadura |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
US20080160040A1 (en) * | 2004-04-15 | 2008-07-03 | Ghim Shin-Je | Plant-produced compositions for treating papillomavirus infection and related methods |
GB0413510D0 (en) * | 2004-06-16 | 2004-07-21 | Glaxosmithkline Biolog Sa | Vaccine |
US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
JP2008502633A (ja) * | 2004-06-16 | 2008-01-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Hpv16およびhpv18ならびにhpv31、45または52から選ばれる少なくとも1つの別のhpv型に対するワクチン |
US8399610B2 (en) * | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
GB0417430D0 (en) * | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
BRPI0607097B8 (pt) * | 2005-02-01 | 2021-05-25 | The Gorvernment Of The United States Of America Repres By The Secretary Depart Of Health And Human S | uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus |
US7691579B2 (en) | 2005-04-15 | 2010-04-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
KR20080005585A (ko) * | 2005-04-26 | 2008-01-14 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
MX2007013475A (es) * | 2005-04-26 | 2008-04-02 | Glaxosmithkline Biolog Sa | Vacuna. |
CN1328287C (zh) * | 2005-12-29 | 2007-07-25 | 西安交通大学 | Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途 |
KR100904844B1 (ko) * | 2006-08-28 | 2009-06-25 | 성균관대학교산학협력단 | 인유두종 바이러스(hpv)유전자를 포함하는자궁경부암의 치료 또는 예방용 dna 백신 |
PL2601969T3 (pl) * | 2006-09-29 | 2016-10-31 | Preparaty szczepionki przeciw norowirusowi | |
US20100272753A1 (en) * | 2006-10-26 | 2010-10-28 | The Johns Hopkins University | Recombinant Adenovirus Vaccines |
WO2008115631A2 (en) * | 2007-02-08 | 2008-09-25 | University Of Louisville Research Foundation, Inc. | Plant-produced compositions for treating papillomavirus infection and related methods |
US7709010B2 (en) * | 2007-03-09 | 2010-05-04 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
BRPI0815818A2 (pt) * | 2007-04-29 | 2016-08-02 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | proteína l1 truncada do papiloma vírus humano tipo 18 |
WO2008134934A1 (en) * | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | A truncated l1 protein of human papillomavirus 16 |
BRPI0810951B8 (pt) * | 2007-05-29 | 2021-05-25 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv |
CN101952320B (zh) * | 2007-06-18 | 2013-08-14 | 上海泽润安珂生物制药有限公司 | 具有免疫原性的物质 |
US8088392B2 (en) * | 2007-06-18 | 2012-01-03 | Yunxu Cao | Capsid proteins and uses therefore |
KR20150129042A (ko) | 2007-09-18 | 2015-11-18 | 다케다 백신즈 인코포레이티드 | 노로바이러스에 대한 보호면역반응을 제공하는 방법 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
US8100843B2 (en) * | 2009-03-24 | 2012-01-24 | GM Global Technology Operations LLC | Shape memory polymer medical cast |
JP2012530505A (ja) * | 2009-06-25 | 2012-12-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規ヒトパピローマウイルス(hpv)タンパク質構築物及びhpv疾患の予防におけるそれらの使用 |
CN102178944A (zh) * | 2010-09-17 | 2011-09-14 | 大连雅立峰生物制药有限公司 | 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用 |
EP3299030B1 (en) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
CN102552897B (zh) * | 2012-01-18 | 2013-10-30 | 广东华南联合疫苗开发院有限公司 | 一种宫颈癌预防性vlp疫苗 |
KR101559622B1 (ko) | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
CN104211782B (zh) * | 2013-06-04 | 2017-11-17 | 厦门大学 | 截短的人乳头瘤病毒45型l1蛋白 |
US10799574B2 (en) * | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
AU2015335652B2 (en) * | 2014-10-24 | 2020-07-02 | Hpvvax, Llc. | Cancer and skin lesion treatment |
WO2017147475A1 (en) * | 2016-02-27 | 2017-08-31 | Hpvvax, Llc | Method and composition for treating cancer or skin lesion using a vaccine |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9113809D0 (en) | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
EP1298211B1 (en) | 1991-07-19 | 2006-07-12 | The University Of Queensland | Polynucleotide segment of HPV16 Genome |
DE122007000096I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5618536A (en) | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
PT1618888E (pt) | 1993-03-09 | 2011-04-08 | Univ Rochester | Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus |
CN1087176C (zh) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | 含有3-o脱酰基单磷酰脂a的疫苗制剂 |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
CZ336696A3 (en) | 1994-05-16 | 1997-07-16 | Merck & Co Inc | Isolated and purified proteins of papillomavirus and process for preparing thereof |
ATE325875T1 (de) | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
JP3693449B2 (ja) | 1996-04-05 | 2005-09-07 | 三菱製紙株式会社 | 抗菌防黴剤およびそれを含有する繊維状物質 |
WO1998044944A2 (en) | 1997-04-08 | 1998-10-15 | Merck & Co., Inc. | Stabilized human papillomavirus formulations |
EP1700911B1 (en) * | 1997-09-05 | 2016-04-06 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs) |
GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
PL343429A1 (en) | 1998-03-09 | 2001-08-13 | Smithkline Beecham Biolog | Combined vaccine compositions |
GB9806666D0 (en) | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
EA200100236A1 (ru) | 1998-08-14 | 2001-08-27 | Мерк Энд Ко., Инк. | Способ очистки вирусных частиц, подобных вирусу папилломы человека |
WO2000009699A2 (en) | 1998-08-14 | 2000-02-24 | Chiron Corporation | Method for producing yeast expressed hpv types 6 and 16 capsid proteins |
EP2266604A3 (en) | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
KR20010093290A (ko) | 1999-02-05 | 2001-10-27 | 폴락 돈나 엘. | 사람 파필로마바이러스 백신 제제 |
US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
CZ20022643A3 (cs) | 2000-01-31 | 2003-02-12 | Smithkline Beecham Biologicals S. A. | Farmaceutický prostředek |
US6908613B2 (en) | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
WO2002004007A2 (en) * | 2000-07-06 | 2002-01-17 | Georgetown University | Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
AU2003217413A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
NZ540811A (en) | 2002-12-20 | 2007-03-30 | Glaxosmithkline Biolog S | Use of HPV 16 and HPV 18 VLPs in the prevention of infection or disease caused by one or more of the group of oncogenic HPV types excluding types 16 and 18 |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
-
2002
- 2002-03-18 GB GBGB0206360.0A patent/GB0206360D0/en not_active Ceased
-
2003
- 2003-03-17 MY MYPI20030925A patent/MY139031A/en unknown
- 2003-03-17 BR BR0308444-2A patent/BR0308444A/pt not_active Application Discontinuation
- 2003-03-17 KR KR10-2004-7014693A patent/KR20050002868A/ko active Application Filing
- 2003-03-17 OA OA1200400239A patent/OA12787A/en unknown
- 2003-03-17 AU AU2003218787A patent/AU2003218787B2/en active Active
- 2003-03-17 US US10/508,222 patent/US7217419B2/en not_active Expired - Lifetime
- 2003-03-17 IL IL16381403A patent/IL163814A0/xx unknown
- 2003-03-17 WO PCT/EP2003/002826 patent/WO2003077942A2/en active Application Filing
- 2003-03-17 UA UA20040907208A patent/UA85536C2/ru unknown
- 2003-03-17 CN CNB038063476A patent/CN100528226C/zh not_active Expired - Lifetime
- 2003-03-17 AP APAP/P/2004/003136A patent/AP1872A/en active
- 2003-03-17 NZ NZ535085A patent/NZ535085A/en not_active IP Right Cessation
- 2003-03-17 EP EP03712047A patent/EP1492562A2/en not_active Ceased
- 2003-03-17 EA EA200401064A patent/EA011477B1/ru active Protection Beyond IP Right Term
- 2003-03-17 KR KR1020107028371A patent/KR20110009249A/ko not_active Application Discontinuation
- 2003-03-17 JP JP2003575995A patent/JP2005524674A/ja active Pending
- 2003-03-17 PL PL372937A patent/PL212981B1/pl unknown
- 2003-03-17 CA CA2479304A patent/CA2479304C/en not_active Expired - Lifetime
- 2003-03-17 MX MXPA04009060A patent/MXPA04009060A/es active IP Right Grant
- 2003-03-17 EP EP08171147A patent/EP2044953A1/en not_active Withdrawn
- 2003-03-18 TW TW092105904A patent/TW200400046A/zh unknown
- 2003-03-18 AR ARP030100944A patent/AR039005A1/es unknown
-
2004
- 2004-08-26 IS IS7426A patent/IS7426A/is unknown
- 2004-08-30 IL IL163814A patent/IL163814A/en active Protection Beyond IP Right Term
- 2004-09-02 ZA ZA2004/07029A patent/ZA200407029B/en unknown
- 2004-09-17 EC EC2004005300A patent/ECSP045300A/es unknown
- 2004-10-12 NO NO20044326A patent/NO20044326L/no not_active Application Discontinuation
-
2007
- 2007-05-10 US US11/746,841 patent/US7416846B2/en not_active Expired - Lifetime
-
2008
- 2008-07-18 US US12/175,874 patent/US7815915B2/en not_active Expired - Lifetime
-
2009
- 2009-12-10 JP JP2009280524A patent/JP2010090158A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200401064A1 (ru) | Вирусоподобные частицы из вируса папилломы человека | |
DE60130987D1 (de) | Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps) | |
EA200701633A1 (ru) | Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1 | |
EA200500584A1 (ru) | Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c | |
EA200400241A1 (ru) | Направленные к мишени мультимерные контрастные вещества, основанные на пептидах | |
ATE267211T1 (de) | Impfstoff gegen hpv | |
MXPA05009580A (es) | Vacuna contra el virus de la influenza. | |
DE69434383D1 (de) | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen | |
DE60334205D1 (en) | Heterocyclische sulfonamid-hepatitis-c-virus-hemmer | |
BR9814487A (pt) | "vacina" | |
NO20052071L (no) | Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer. | |
IS7533A (is) | Lifrarbólgu C-veirutálmar | |
DK1292328T3 (da) | Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse | |
EA199700281A1 (ru) | Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц | |
ATE333500T1 (de) | Virus des porzinen reproduktiven und respiratorischen syndroms und dessen verwendung | |
EA200300334A1 (ru) | Новая соль периндоприла и содержащие ее фармацевтические композиции | |
EA200601217A1 (ru) | Новые конденсированные пирролокарбазолы | |
EA200201138A1 (ru) | Пептид, модулирующий рецептор тромбопоэтина | |
EA200601219A1 (ru) | Новые конденсированные пирролокарбазолы | |
ATE473997T1 (de) | Zur bildung von partikeln fähiges hbv-precore- protein | |
ATE534666T1 (de) | Antikörper gegen den hepatitis c-virus e1e2 komplex und pharmazeutische zusammensetzungen | |
DE69812597D1 (de) | Peptide zur Inhibition von HPV E7 Proteinen | |
ATE467424T1 (de) | Escape-mutanten des newcastle-disease-virus als marker-vakzine | |
DE50015132D1 (de) | Chimäre virus-ähnliche partikel bzw. chimäre capsomere von bpv (bovine papilloma virus) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ND4A | Extension of term of a eurasian patent |